Here are four stocks with buy rank and strong income characteristics for investors to consider today, January 14th:

Bristol-Myers Squibb Company (BMY): This developer and manufacturer of biopharmaceutical products has witnessed the Zacks Consensus Estimate for its current year earnings increasing 3.2% over the last 60 days.

Bristol-Myers Squibb Company Price and Consensus

This Zacks Rank #2 (Buy) company has a dividend yield of 2.76%, compared with the industry average of 2.65%. Its five-year average dividend yield is 2.71%.

Bristol-Myers Squibb Company Dividend Yield (TTM)

Apollo Investment Corporation (AINV): This business development company has witnessed the Zacks Consensus Estimate for its current year earnings increasing 1.6% over the last 60 days.

Apollo Investment Corporation Price and Consensus

This Zacks Rank #2 (Buy) company has a dividend yield of 10.25%, compared with the industry average of 8.38%. Its five-year average dividend yield is 11.49%.

Apollo Investment Corporation Dividend Yield (TTM)

The Buckle, Inc. (BKE): This retailer of casual apparel, footwear and accessories has witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.7% over the last 60 days.

Buckle, Inc. (The) Price and Consensus

This Zacks Rank #1 (Strong Buy) company has a dividend yield of 4.62%, compared with the industry average of 0.00%. Its five-year average dividend yield is 4.22%.

Buckle, Inc. (The) Dividend Yield (TTM)

The Andersons, Inc. (ANDE): This agriculture company has witnessed the Zacks Consensus Estimate for its current year earnings increasing 64.6% over the last 60 days.

The Andersons, Inc. Price and Consensus

This Zacks Rank #1 (Strong Buy) company has a dividend yield of 2.84%, compared with the industry average of 0.00%. Its five-year average dividend yield is 1.92%.

The Andersons, Inc. Dividend Yield (TTM)

See the full list of top ranked stocks here.

Find more top income stocks with some of our great premium screens.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
 
Buckle, Inc. (The) (BKE): Free Stock Analysis Report
 
The Andersons, Inc. (ANDE): Free Stock Analysis Report
 
Apollo Investment Corporation (AINV): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research